title: [Cerebrolysin and magnesium-B6 in the treatment of side effects of psychotropic drugs].
abstract: 51 patients were observed. Schizophrenia was diagnosed in 31 patients and endogenous depression in 20 cases. All the patients had extrapyramidal and somato-vegetative side effects of neuroleptics and antidepressive drugs, and were resistant to conventional corrective therapy for at least a period of 3 weeks. In addition to current treatment of both basic disease and adverse effects, cerebrolysin was administered (5-10 ml i.v./dr, during 28 days) and magme B6 (20-30 ml per os during 21 days). By the treatment end-point either moderate or marked reduction of extrapyramidal disorders (according to ESRS) was observed in 74.4% of patients treated by cerebrolysin and in 72.2% treated by magne B6; somato-vegetative adverse effects reduced (by SARS) in 85.8% and in 83.8% respectively. Both drugs showed equally high efficacy against hyperkinetic and cardiovascular side effects (symptoms relief was in 59-62% and 65-69%, respectively). Cerebrolysin is more preferable in cases of side vegetative events, dysomnia and dysuria; magne B6 was more effective in correction of akineto-hypertonic and hyperkinetic-hypertonic syndromes as well as in cholinolytic side effects.
authors.forename: G P
authors.initials: GP
authors.lastname: Panteleeva
authors.forename: V V
authors.initials: VV
authors.lastname: Bondar'
authors.forename: N I
authors.initials: NI
authors.lastname: Krasnikova
authors.forename: V A
authors.initials: VA
authors.lastname: Raiushkin
mesh_terms: D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000009:adverse effects*; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000596:Amino Acids; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D011619:Psychotropic Drugs; C006952:cerebrolysin; D008274:Magnesium; D011736:Pyridoxine
vernacular_title: Tserebrolizin i magne B6 v terapii pobochnykh éffektov psikhotropnykh sredstv.